GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies according to eyeforpharma
They will announce their intentions at the eyeforpharma Barcelona summit in March where a ‘new business plan’ for the industry comprising collaboration, culture and customer-centricity will be proposed.
Speaking ahead of the conference, David Epstein, CEO pharmaceuticals, Novartis, said: “This will expand on our ‘patient declaration’ for holding the people in our company accountable, to taking a large step forward in terms of patient safety, access, transparency and involving them in clinical trials.
“I am also working on changing the values of the company, being much more focused on courage, collaboration, integrity and quality, as well as performance - the very things our customers would expect of us.”
Epstein also joins leaders from LEO Pharma, ViiV Healthcare, Almirall, GSK, Eli Lilly, Janssen, Teva, Celgene and UCB on the stage.
The eyeforpharma Barcelons summit will take place on 15-17 March at the Centre Convencions Internacional Barcelona.
To register for the event, click here.